Skip to content
RoundsRx
โŒ• /
Dashboard
Overview
Recent
Rotations
ICU / Critical Care โ€บ
Sepsis & Septic Shock
COPD Exacerbation
ARDS
Airway & Ventilator Management
Cardiogenic Shock
DKA / HHS
Hypertensive Emergency
Hepatic Encephalopathy
Status Epilepticus
Upper GI Bleed
Post-Cardiac Arrest
Afib with RVR
ADHF
Pulmonary Embolism
Hyperkalemia
Alcohol Withdrawal
Acute Pancreatitis
Acute Ischemic Stroke
Mesenteric Ischemia
Fat Embolism Syndrome
Malignant Hyperthermia
Intubation / RSI
ICU Sedation & Delirium
Cardiology โ€บ
Heart Failure (Chronic / GDMT)
Atrial Fibrillation
STEMI
NSTEMI / Unstable Angina
Arrhythmias
Pericarditis
Aortic Dissection
Infective Endocarditis
Valvular Heart Disease
Syncope
Heart Block & Bradycardia
Myocarditis
Hypertrophic Cardiomyopathy
ACS Overview
Aortic Stenosis
Mitral Regurgitation
Pulmonology โ€บ
COPD
Asthma
Pleural Effusion
Pneumonia
Massive Transfusion Protocol
Brain Death Evaluation
Pulmonary Nodule
PFT Interpretation
Pneumothorax
Obstructive Sleep Apnea
Interstitial Lung Disease
Hemoptysis
Sarcoidosis
Gastroenterology โ€บ
Upper GI Bleed
Lower GI Bleed
Hepatic Encephalopathy
Cirrhosis & Ascites
SBP
Acute Pancreatitis
Mesenteric Ischemia
C. diff
Cardiac Tamponade
Pulmonary Hypertension
Stable Angina & Chronic CAD
Alcoholic Hepatitis
Hepatorenal Syndrome
Refeeding Syndrome
Gallstone Pancreatitis
Autoimmune Hepatitis
PBC / PSC
Acute Liver Failure
Bowel Obstruction
Nephrology โ€บ
Acute Kidney Injury
Chronic Kidney Disease
Hyperkalemia
Hyponatremia
Acid-Base Disorders
Dialysis Indications
Hypernatremia
Renal Transplant Medicine
Infectious Disease โ€บ
Sepsis & Septic Shock
Meningitis
UTI & Pyelonephritis
HIV Essentials
Endocarditis
C. difficile
Pneumonia
Osteomyelitis
Necrotizing Fasciitis
Neurology โ€บ
Status Epilepticus
Acute Ischemic Stroke
AMS & Delirium
Guillain-Barrรฉ
Myasthenic Crisis
Heat Stroke
PRES
Emergency Medicine โ€บ
Post-Cardiac Arrest (ROSC)
Inflammatory Bowel Disease
SBO & Ileus
Cholangitis & Cholecystitis
Hypertensive Emergency
DKA / HHS
Alcohol Withdrawal
Chest Pain Workup
Anaphylaxis
Toxicology & Overdose
Intubation / RSI
Acute Limb Ischemia
Necrotizing Fasciitis
General Wards โ€บ
VTE Prophylaxis & Treatment
Discharge Planning
Admission Orders & I-PASS
Anemia Workup
Cellulitis
Falls & Delirium Prevention
Inpatient Diabetes Management
Hematology / Oncology โ€บ
Neutropenic Fever
DIC
Intracerebral Hemorrhage
Headache & Migraine
Spinal Cord Compression
Burns
Hypothermia & Drowning
TTP / HUS
Tumor Lysis Syndrome
Sickle Cell
Transfusion Medicine
Transfusion Reactions
Trauma Survey
Acute Abdomen
HIT
ITP (Immune Thrombocytopenia)
Oncologic Emergencies
Pancytopenia
Chemotherapy Toxicities
Lymphoma
Multiple Myeloma
Acute Leukemia
Anticoagulation
Anemia Workup
Hemolytic Anemia
Amyloidosis
Endocrinology โ€บ
Inpatient Diabetes & Insulin
Thyroid Storm / Myxedema
Adrenal Crisis
SIADH / Diabetes Insipidus
Hypercalcemia
VTE Prophylaxis
Delirium
Discharge Planning
HHS
Myxedema Coma
Pheochromocytoma
Hypoglycemia
Hypocalcemia
Diabetes Insipidus
Cushing's Syndrome
Hyperthyroidism / Graves'
Hyperviscosity Syndrome
Primary Aldosteronism
Hypothyroidism
SVC Syndrome
Inpatient Diabetes Management
Corticosteroids
Rheumatology โ€บ
Gout & Pseudogout
SLE Flare
Vasculitis
Rheumatoid Arthritis
Antiphospholipid Syndrome
Scleroderma & Renal Crisis
Palliative Care โ€บ
Goals of Care & Symptom Mgmt
Hospice Eligibility
Opioid Rotation & Pain
Palliative Extubation
Ambulatory / Outpatient โ€บ
Preventive Care & Screening
Outpatient Diabetes
Obesity & GLP-1 Agents
Smoking Cessation
Septic Arthritis
Code Status & Advance Directives
Family Meeting Framework
Hypoparathyroidism
PMR & Giant Cell Arteritis
Myositis
Prognostication Tools
Symptom Management
Spondyloarthropathies
Quick Reference
Antibiotic Guide Analgesia Guide Sedation Guide Bowel Regimen Electrolyte Replacement Pain Management & Conversions Drug Interactions Anticoag Reversal IV Fluid Guide Inotropes Guide Vasopressors Insulin Guide Code Blue & Rapid Response Procedures Guide ECG Interpretation Lab Interpretation Radiology Quick Ref GCS Pocket Card Admission Orders & I-PASS Landmark Trials
Tools
๐Ÿ’Ž Clinical Pearls ๐Ÿง  Pimp Me Quiz ๐Ÿงฎ Clinical Calculators ๐Ÿ“ฐ What's New ๐ŸŽ“ Intern Survival Guide โœ… Rounding Checklists ๐Ÿฉบ Procedure Guides โšก Electrolyte Replacement ๐Ÿ’ง IV Fluids Guide ๐Ÿฉธ Transfusion Guide ๐Ÿ’“ ECG Pattern Guide ๐Ÿงช Lab Interpretation Guide ๐Ÿ“ฑ QR Poster ๐Ÿ”— Resources ๐ŸŽ™๏ธ Channels & Podcasts ๐ŸŽฎ Medical Games ๐Ÿ›๏ธ Famous Cases ๐ŸŽฌ Media Library
โ„น๏ธ About
Available offline
Heme/OncCommon

Transfusion Medicine

When to transfuse, what products to use, and how to manage reactions. Restrictive is better for most patients. Know the thresholds and the reactions -you'll order blood products daily.
๐Ÿฉธ  Transfusion Thresholds
ProductThresholdEvidence
pRBCs -general
RESTRICTIVE
Hgb < 7 g/dLTRICC, 1999: restrictive (7) non-inferior to liberal (10) in ICU. TRICS-III, 2017: confirmed in cardiac surgery.
pRBCs -ACSHgb < 8 g/dL (or symptomatic anemia)REALITY, 2021: restrictive (8) vs liberal (10) -non-inferior for 30-day MACE in MI.
pRBCs -active bleedingHgb < 7โ€“8, but transfuse to symptoms/hemodynamicsMTP: 1:1:1 ratio PROPPR, 2015 (pRBC:FFP:platelets). Don't wait for lab values in massive hemorrhage.
Platelets -general< 10,000 (prophylactic)Higher thresholds for active bleeding (< 50K), neurosurgery (< 100K), or procedures.
FFPActive bleeding + INR > 1.515 mL/kg. Or 4F-PCC for warfarin reversal (faster, less volume).
CryoprecipitateFibrinogen < 100โ€“150 (DIC, massive transfusion)10 units raises fibrinogen ~50โ€“70 mg/dL. Key product in DIC.
๐Ÿ”„ Updated Practice: Old teaching: transfuse when Hgb <10 ("10/30 rule"). Current evidence: restrictive strategy (Hgb <7) is as safe or safer than liberal (Hgb <10) in most ICU patients (TRICC, 1999; TRISS, 2014). Exceptions: active ACS (transfuse <8), symptomatic anemia, active hemorrhage. For upper GI bleed, restrictive transfusion (Hgb <7) actually IMPROVED survival (Villanueva, 2013).
๐Ÿ’‰  Blood Products
ProductContainsExpected EffectSpecial Considerations
pRBCsRed blood cells in additive solutionโ†‘ Hgb ~1 g/dL per unitType & screen required. Irradiate if immunocompromised (prevent TA-GVHD). CMV-negative or leukoreduced for transplant candidates.
PlateletsPlatelets (apheresis or pooled)โ†‘ 30,000โ€“50,000 per unitABO-compatible preferred. Room temperature storage (not refrigerated). 5-day shelf life. Highest bacterial contamination risk of all blood products.
FFPAll clotting factorsโ†‘ factor levels ~20โ€“30%ABO-compatible required. Thaw time ~30 min. Volume ~250 mL/unit (risk of TACO).
CryoprecipitateFibrinogen, Factor VIII, vWF, Factor XIIIโ†‘ fibrinogen ~50โ€“70 mg/dL per 10 unitsKey for DIC, massive transfusion, factor XIII deficiency. Pooled (10 units = 1 dose).
โš ๏ธ  Transfusion Reactions
First step in ANY suspected reaction: STOP the transfusion. Maintain IV access. Check vitals. Send a clerical check + blood sample to the blood bank.
ReactionTimingFeaturesManagement
Acute hemolytic (ABO mismatch)MinutesFever, flank pain, dark urine, hypotension, DIC. Most dangerous. Usually clerical error.STOP immediately. IVF (prevent renal failure), send direct Coombs + repeat type & screen. Supportive ICU care.
Febrile non-hemolytic (FNHTR)1โ€“6 hoursFever, rigors. Most common reaction. Cytokines from donor WBCs.Stop, rule out hemolytic. Acetaminophen. Leukoreduced products prevent recurrence.
Allergic (mild)DuringUrticaria, pruritus. No fever or hemodynamic changes.Stop temporarily. Diphenhydramine 25โ€“50 mg IV. Can resume slowly if mild.
AnaphylacticMinutesHypotension, bronchospasm, angioedema. Often in IgA-deficient patients (anti-IgA antibodies).Epinephrine 0.3โ€“0.5 mg IM. IVF, steroids, bronchodilators. Future: washed or IgA-deficient products.
TRALIโ‰ค 6 hoursAcute respiratory distress + bilateral infiltrates + hypoxia within 6h. No volume overload. Caused by donor antibodies activating recipient neutrophils in lungs.Supportive (Oโ‚‚, ventilation). Diuretics do NOT help (not a volume issue). Usually resolves 48โ€“96h. Report to blood bank.
TACOโ‰ค 6 hoursVolume overload โ†’ pulmonary edema, HTN, JVD. Distinguished from TRALI by: elevated BNP, response to diuretics, hypertension.Diuretics. Slow transfusion rate for future products
๐Ÿ”  Overview
Overview

Blood product transfusion is one of the most common inpatient procedures. Restrictive thresholds (Hgb < 7) are standard for most patients [TRICC, 1999; TRISS, 2014] -liberal transfusion does not improve outcomes and may worsen them. In acute coronary syndrome, threshold is Hgb < 8. Always transfuse 1 unit at a time and recheck before ordering more. Massive transfusion protocol (MTP): 1:1:1 ratio of pRBC:FFP:platelets + TXA 1g IV [CRASH-2, 2010; PROPPR, 2015]. Key reactions to recognize: TRALI (non-cardiogenic pulmonary edema, normal BNP, within 6h) vs TACO (volume overload, elevated BNP, responds to diuretics). Stop transfusion immediately for any suspected reaction.

๐Ÿงช  Workup
Workup
  • Type & screen -ABO + Rh typing + antibody screen. Required before all transfusions. Valid for 72h in recently transfused/pregnant patients.
  • Crossmatch -for elective/non-emergent transfusion. Takes 30-60 min. In emergency: use O-negative (universal donor) while crossmatch pending.
  • CBC -Hgb (transfusion threshold), platelet count (threshold 10K for prophylactic, 50K for invasive procedure, 100K for neurosurgery)
  • Coagulation studies -PT/INR (FFP threshold: INR > 1.5 with active bleeding), fibrinogen (cryoprecipitate threshold: < 100-150 mg/dL)
  • Direct Coombs (DAT) -if suspected transfusion reaction or hemolytic anemia. Positive = antibodies coating RBCs.
  • Indirect Coombs (IAT) -detects circulating antibodies. Part of antibody screen. Positive โ†’ need antigen-negative units.
  • Post-transfusion Hgb -check 1-2h after transfusion. Expected rise: ~1 g/dL per unit pRBC. If less โ†’ consider ongoing bleeding, hemolysis, or hypersplenism.
  • For suspected reaction: stop transfusion โ†’ send bag + tubing to blood bank โ†’ direct Coombs โ†’ free hemoglobin (plasma/urine) โ†’ haptoglobin โ†’ repeat type & screen โ†’ UA for hemoglobinuria โ†’ chest imaging if respiratory symptoms
๐Ÿšจ  Management
Management
  • Transfusion thresholds (restrictive):
    • Hgb < 7 -most hospitalized patients [TRICC, 1999; TRISS, 2014; FOCUS, 2011]
    • Hgb < 8 -acute coronary syndrome, symptomatic anemia, acute GI bleed with hemodynamic instability
    • Hgb < 10 -rarely indicated (active MI with ongoing ischemia, severe symptomatic anemia)
    • Platelets < 10K -prophylactic (no bleeding)
    • Platelets < 50K -active bleeding or invasive procedure
    • Platelets < 100K -neurosurgery, ocular surgery
    • FFP -INR > 1.5 with active bleeding. NOT for "correcting" INR without bleeding.
    • Cryoprecipitate -fibrinogen < 100-150 mg/dL
  • Massive transfusion protocol (MTP): pRBC:FFP:platelets = 1:1:1 PROPPR, 2015. Activate early in hemorrhagic shock. TXA 1g IV within 3h of injury CRASH-2, 2010. Calcium gluconate 1g after every 4 units (citrate chelates calcium).
  • Transfusion reactions:
    • Febrile non-hemolytic (most common): fever + rigors within 1-6h. Stop, rule out hemolytic. Acetaminophen. Resume with leukoreduced products.
    • Acute hemolytic: ABO incompatibility. Fever, flank pain, hemoglobinuria, DIC. STOP immediately. Aggressive IVF. Send workup.
    • TRALI: bilateral infiltrates + hypoxia within 6h. Normal BNP. Supportive care (no diuretics -not volume overload). Resolves 48-72h.
    • TACO: volume overload. Elevated BNP. Responds to furosemide. Prevention: slow rate, furosemide between units in high-risk.
    • Allergic: urticaria (minor โ†’ diphenhydramine, resume). Anaphylaxis (IgA deficiency) โ†’ epinephrine, stop, use washed products.
  • Special products: irradiated (prevent TA-GVHD in immunocompromised), CMV-negative (transplant recipients), leukoreduced (prevent febrile reactions + CMV), washed (IgA deficiency, severe allergic reactions)
๐Ÿ“‹  On Rounds
How do you distinguish TRALI from TACO?
Both present with respiratory distress + bilateral infiltrates within 6h of transfusion. TRALI: non-cardiogenic pulmonary edema (BNP normal or low, hypotension, no JVD, does NOT respond to diuretics). Caused by donor antibodies. TACO: cardiogenic volume overload (BNP elevated, hypertension, JVD, responds to diuretics). Risk factors: CHF, CKD, rapid infusion rate, multiple units. Key distinguisher: give furosemide. If they improve โ†’ TACO.
Why Hgb 7, not 10?
TRICC, 1999 randomized ICU patients to restrictive (Hgb 7) vs liberal (Hgb 10) transfusion. Restrictive was non-inferior for 30-day mortality and had fewer cardiac events. Multiple subsequent trials confirmed this across cardiac surgery TRICS-III, 2017, GI bleed Villanueva, 2013, and hip surgery FOCUS, 2011.
What is TRALI and how do you differentiate it from TACO?
Both present with respiratory distress during/after transfusion, but treatment is opposite. TRALI (Transfusion-Related Acute Lung Injury): non-cardiogenic pulmonary edema. Onset within 6h. Bilateral infiltrates on CXR. NO signs of volume overload (BNP normal/low, no JVD, no S3). Due to donor antibodies activating recipient neutrophils โ†’ capillary leak. Treatment: supportive (Oโ‚‚, intubation if needed, NO diuretics).
What is the transfusion threshold for most hospitalized patients?
Restrictive threshold: Hgb < 7 g/dL for most hospitalized patients. TRICC, 1999 and TRISS, 2014: restrictive (Hgb < 7) was non-inferior to liberal (Hgb < 10) for mortality. Liberal transfusion did NOT improve outcomes and increased complications. Exception: Hgb < 8 for ACS/active cardiac ischemia (the MINT trial MINT, 2023 suggested possible benefit, though not definitive).
โ“ How do you differentiate TRALI from TACO?
TRALI = non-cardiogenic pulmonary edema. Normal BNP, bilateral infiltrates within 6h, no fluid overload signs, does NOT respond to diuretics. Supportive care only -resolves 48-72h. TACO = volume overload. Elevated BNP, responds to furosemide, often hypertensive. Prevention: slow transfusion rate, furosemide between units in HF/CKD patients.
โ“ What is the expected hemoglobin rise per unit of pRBC transfused?
~1 g/dL per unit in a 70 kg adult. If the post-transfusion Hgb rise is less than expected, consider: (1) ongoing hemorrhage, (2) hemolysis (check Coombs, LDH, haptoglobin), (3) hypersplenism, (4) volume overload diluting the measurement, (5) lab draw from a diluted line.
โ“ When do you give cryoprecipitate and what does it contain?
Cryoprecipitate contains: fibrinogen (most important), Factor VIII, Factor XIII, vWF, and fibronectin. Give when fibrinogen < 100-150 mg/dL (DIC, massive transfusion, post-thrombolytics). Dose: 10 units (1 pool) raises fibrinogen ~70 mg/dL. In massive hemorrhage, check fibrinogen early and replace aggressively -it is the first factor to become critically depleted.
โ“ What is a delayed hemolytic transfusion reaction (DHTR)?
DHTR occurs 3-14 days after transfusion due to anamnestic antibody response (patient was previously sensitized but antibody titer dropped below detection). Presents with: unexplained Hgb drop, new jaundice, dark urine, positive DAT. Especially dangerous in SCD patients -can cause hyperhemolysis (destruction of both transfused AND native RBCs). Prevention: extended phenotype matching.
โ“ What does TXA do and when is it indicated in massive hemorrhage?
Tranexamic acid (TXA) inhibits fibrinolysis by blocking plasmin. Give 1g IV within 3 hours of hemorrhage onset -later administration may be harmful. Evidence: CRASH-2, 2010 -reduced mortality in trauma. WOMAN, 2017 -reduced death from postpartum hemorrhage. No benefit shown in GI bleeding HALT-IT, 2020. Include in all massive transfusion protocols.
Clinical Examples
๐Ÿ“‹ Case 1, Acute Hemolytic Transfusion Reaction

Patient: 62M receiving unit of pRBCs for Hgb 6.2. Within 15 min: rigors, fever 39.8ยฐC, severe flank pain, dark urine. BP 82/48. Nursing notes: unit labeled "type A" but patient is "type O."

Key findings: ABO-incompatible transfusion, the most dangerous transfusion reaction. Patient (type O) has preformed anti-A antibodies โ†’ immediate intravascular hemolysis โ†’ DIC, shock, renal failure. Almost always a clerical/labeling error.

Management:

  • STOP transfusion immediately, do NOT continue even a drop
  • Maintain IV access with NS. Aggressive IVF to maintain UOP > 1 mL/kg/hr (prevent hemoglobin-induced AKI)
  • Send: DAT, repeat type and crossmatch, free hemoglobin, LDH, haptoglobin, fibrinogen, DIC panel
  • Return blood bag + tubing to blood bank for investigation
  • Monitor for DIC (fibrinogen, PT/PTT, D-dimer), replace products as needed

Teaching point: Acute hemolytic reactions are almost always human error, wrong blood to wrong patient. The bedside nurse check (patient ID + unit label + blood bank tag) is the last line of defense. Two-person verification at bedside prevents this lethal error.

๐Ÿ“‹ Case 2, TRALI vs TACO

Patient: 75F with HFrEF (EF 30%), received 2 units pRBCs for Hgb 6.8 (GI bleed). 4 hours after second unit: acute dyspnea, SpOโ‚‚ 84%, bilateral crackles, HTN (180/95). CXR: bilateral pulmonary infiltrates. BNP 2400.

Key findings: Elevated BNP + hypertension + responds to diuresis = TACO (transfusion-associated circulatory overload), NOT TRALI. TRALI would have normal BNP, hypotension, and would NOT respond to furosemide. This patient's underlying HF + rapid transfusion โ†’ volume overload.

Management:

  • Furosemide 40 mg IV (diagnostic AND therapeutic, TACO responds, TRALI does not)
  • Upright positioning, supplemental Oโ‚‚, BiPAP if needed
  • If this were TRALI: supportive Oโ‚‚ only, NO diuretics, may need intubation, resolves 48-72h
  • Prevention for future transfusions: slow rate (1 unit over 3-4h), furosemide 20 mg IV between units, limit to 1 unit at a time
  • Report to blood bank (both TACO and TRALI are reportable)

Teaching point: The BNP is the best discriminator: TACO = elevated BNP (volume overload). TRALI = normal BNP (capillary leak). When in doubt, give furosemide, if the patient improves, it's TACO. TACO is now more common than TRALI since leukoreduction reduced TRALI incidence.

๐Ÿ“‹ Case 3, Massive Transfusion Protocol

Patient: 32F with ruptured ectopic pregnancy, HR 140, BP 68/30, Hgb 4.2. Actively hemorrhaging. MTP activated.

Key findings: Class IV hemorrhagic shock (> 40% blood volume loss). Massive transfusion protocol (MTP) = โ‰ฅ 10 units pRBCs in 24h or โ‰ฅ 4 units in 1h. Goal: 1:1:1 ratio (pRBC:FFP:platelets) per PROPPR trial.

Management:

  • MTP packs: 6 pRBC + 6 FFP + 1 apheresis platelet (delivered as a cooler from blood bank)
  • 1:1:1 ratio of pRBC:FFP:platelets PROPPR, 2015
  • TXA 1g IV within 3h of hemorrhage onset โ†’ 1g over 8h CRASH-2, 2010
  • Replace calcium: 1g calcium gluconate per 4 units pRBCs (citrate in blood products chelates calcium โ†’ hypocalcemia โ†’ cardiac dysfunction)
  • Check fibrinogen early, give cryo if < 150 (fibrinogen is the first factor to become critically depleted)

Teaching point: The biggest mistakes in massive transfusion: (1) giving crystalloid instead of blood (dilutes coagulation factors), (2) forgetting calcium replacement (citrate toxicity โ†’ cardiac arrest), (3) not checking fibrinogen early (depletes before other factors). Resuscitate with blood, not saline.

๐Ÿ“ฃ Sample Presentation
One-Liner
"Mr. Davis is a 68-year-old who developed rigors, fever 39.2ยฐC, and back pain 20 minutes into a pRBC transfusion. BP dropped from 130/80 to 88/52. Transfusion stopped immediately."
Key Points to Cover on Rounds
Suspected acute hemolytic transfusion reaction (fever + hypotension + back pain during transfusion). Immediate actions: (1) transfusion STOPPED, (2) IV access maintained with NS, (3) patient ID rechecked against blood product -mismatch identified (wrong unit hung). Reaction workup sent: repeat type & screen, direct Coombs (DAT), free hemoglobin, LDH, haptoglobin, UA (hemoglobinuria). Blood bank notified immediately. IVF resuscitation for hypotension. Monitoring for DIC (PT/INR, fibrinogen, D-dimer q4h). Plan: supportive care, if Hgb still needed โ†’ crossmatch new unit with correct sample.
๐Ÿ’Š  Medications
Blood Products & Transfusion Medications
Product / DrugIndication & ThresholdDose / Details
pRBCs (packed red blood cells)Hgb < 7 (general, TRICC); Hgb < 8 (ACS / active cardiac ischemia)1 unit at a time. Expected rise: ~1 g/dL per unit. Recheck Hgb after each unit before ordering more.
Platelets< 10K (prophylactic, no bleeding); < 50K (active bleeding or procedure); < 100K (neurosurgery)1 apheresis unit or 6-pack pooled. Expected rise: 30,000โ€“50,000 per unit. Room temperature storage.
FFP (fresh frozen plasma)INR > 1.5 with active bleeding. NOT for "correcting" INR without bleeding.15 mL/kg (~4 units for 70 kg). ABO-compatible required. ~30 min thaw time. Consider 4F-PCC for faster warfarin reversal.
CryoprecipitateFibrinogen < 150 mg/dL (DIC, massive transfusion, post-thrombolytics)10 units (1 pool). Raises fibrinogen ~50โ€“70 mg/dL. Contains fibrinogen, Factor VIII, vWF, Factor XIII.
Tranexamic acid (TXA)Massive hemorrhage -within 3 hours of onset1g IV over 10 min, then 1g over 8h. CRASH-2, 2010. Inhibits fibrinolysis. Include in all MTP activations.
Premedication
Premedication (acetaminophen 650 mg PO + diphenhydramine 25โ€“50 mg IV/PO) is only indicated if the patient has had a prior febrile or allergic transfusion reaction. Routine premedication for all transfusions is NOT recommended -it delays the transfusion, adds cost, and does not prevent serious reactions (TRALI, hemolytic). Leukoreduction is more effective than premedication for preventing FNHTR.
โšก  Summary
Summary
Threshold
Hgb < 7 for most [TRICC]. Hgb < 8 for ACS. 1 unit raises Hgb ~1 g/dL. Check after each unit before ordering more.
Massive Transfusion
MTP: 1:1:1 ratio (pRBC:FFP:plt). TXA 1g IV within 3h [CRASH-2]. Caยฒโบ repletion (citrate in products chelates Ca). Warm products.
TRALI vs TACO
TRALI: non-cardiogenic edema, normal BNP, no diuretics. TACO: volume overload, elevated BNP, responds to furosemide. BNP is the differentiator.
Febrile Reaction
Fever + rigors during transfusion. Stop. R/O hemolytic reaction: send DAT, free Hgb, LDH, haptoglobin. Most are benign febrile non-hemolytic reactions.
Prevention
Irradiate for immunocompromised (prevent TA-GVHD). CMV-negative for CMV-seronegative transplant patients. Slow rate for CHF/elderly (1 unit over 2-4h).
Type & Screen
Always before transfusion. Emergency: O-negative pRBC (universal donor). Type-specific uncrossmatched next. Full crossmatch safest but takes time.
๐Ÿ“„  One Pager
Transfusion Medicine -Quick Reference Card
Print this page (Ctrl/Cmd + P) for a condensed reference card. All tabs will print on the same page for a complete topic summary.
TRANSFUSION MEDICINE -AT A GLANCE
๐Ÿฉธ Thresholds: Hgb < 7 (general), < 8 (ACS). Platelets < 10K (prophylactic). FFP for INR > 1.5 + bleeding.
๐Ÿงช Workup: Type & screen, crossmatch, CBC, coags, post-transfusion Hgb 1h after โ†’ see Workup tab
โš ๏ธ Reactions: STOP transfusion first. TRALI (normal BNP) vs TACO (elevated BNP) โ†’ see Reactions tab
๐Ÿ’Š Products: pRBC, platelets, FFP, cryo, TXA โ†’ see Medications tab
๐Ÿ“ˆ Monitor: Vitals q15min ร— 1h, watch for reactions, post-transfusion Hgb
๐Ÿ“ฃ Present: Indication, product, reaction workup โ†’ see Rounds tab
๐Ÿ“„  One Pager
Hematology ยท One Pager
Transfusion Medicine
Threshold Hgb < 7 for most. 1:1:1 for MTP. TRALI vs TACO: BNP differentiates. Stop + workup any suspected reaction. Type & screen before all transfusions.
๐Ÿงช Thresholds
Hgb < 7 for most patients [TRICC, TRISS]. Hgb < 8 for active cardiac ischemia. Massive hemorrhage: 1:1:1 ratio (pRBC:FFP:plt) + TXA [CRASH-2].
๐Ÿšจ Reactions
Febrile non-hemolytic (most common): stop, workup, rule out hemolytic. Acute hemolytic: fever + hypotension + back pain โ†’ stop immediately, send DAT, free Hgb, haptoglobin. TRALI: non-cardiogenic edema (normal BNP). TACO: volume overload (high BNP โ†’ furosemide).
๐Ÿ’Š Special Products
Irradiated: immunocompromised (prevent TA-GVHD). CMV-negative: CMV-seroneg transplant patients. Leukoreduced: prevent febrile reactions. Washed: severe allergic reactions (IgA deficiency).
๐Ÿ’Š Key Drugs
pRBCs1 unit raises Hgb ~1 g/dL
FFP10-15 mL/kg (INR correction)
Platelets1 unit raises plt ~30-50K
TXA1g IV (massive hemorrhage)
โš ๏ธ Pitfalls
  • Transfusing above threshold without indication
  • Not checking type & screen
  • Not recognizing TRALI vs TACO (BNP differentiates)
  • Rapid transfusion in CHF/elderly (slow rate, furosemide between units)
RoundsRx ยท Hematology AABB Guidelines 2016 ยท TRICC ยท TRISS ยท CRASH-2
Related Topics
Acute Leukemia (AML / ALL)AmyloidosisAnemia WorkupAnemia WorkupAnticoagulation ManagementChemotherapy Toxicities
© 2026 RoundsRx. All rights reserved. | About | Contact
Unauthorized reproduction, redistribution, or derivative use is prohibited.
VIEW
๐Ÿฉบ Health Check